Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Maria-Novella Piersantelli"'
Autor:
Lorenzo Falsetti, Alberto Maria Marra, Mattia Sampaolesi, Francesca Riccomi, Marta Buzzo, Lorenzo Nobili, Vincenzo Zaccone, Annalisa Marchetti, Maria Novella Piersantelli, Tamira Gentili, Cinzia Nitti, Aldo Salvi
Background According to current guidelines, the presence of right ventricle dysfunction (RVD) in patients with pulmonary embolism (PE) is a turning point for clinical decision making. Right ventricle-arterial coupling (RVAC) is defined as the capabil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::27144f85dac9f1f5e90e8a10edf32248
http://hdl.handle.net/11585/697117
http://hdl.handle.net/11585/697117
Autor:
Alessia Raponi, Lorenzo Falsetti, Mattia Sampaolesi, Aldo Salvi, Cinzia Nitti, Tamira Gentili, Annalisa Marchetti, Maria Novella Piersantelli, Vincenzo Zaccone, Francesca Riccomi
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
Procalcitonin (PCT) is a a marker of bacterial infection. Its prognostic role in the critically-ill patient, however, is still object of debate. Aim of this study was to evaluate the capacity of admission PCT (aPCT) in assessing the prognosis of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7df8aab046ae91cb1a6db15daed70555
https://pubmed.ncbi.nlm.nih.gov/32161314
https://pubmed.ncbi.nlm.nih.gov/32161314
Autor:
Marino Brunori, Arduino Samori, Marco Candela, Luciano Giuliodori, Pietro Leoni, Massimo Catarini, Massimo Offidani, Riccardo Centurioni, Laura Corvatta, Anna Mele, Mario Ferranti, Monica Marconi, Piero Galieni, Maurizio Burattini, Maria-Novella Piersantelli, Giuseppe Visani, Silvia Gentili, Claudia Polloni, Francesco Alesiani
Publikováno v:
British Journal of Haematology. 144:653-659
Summary Maintenance therapy was explored in multiple myeloma (MM) patients after conventional thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD). Patients with newly or relapsed MM obtaining at least minor response after 6 ThaDD c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12ba8553e91ef6161941121d471e586a
https://doi.org/10.1111/j.1365-2141.2008.07495.x
https://doi.org/10.1111/j.1365-2141.2008.07495.x
Autor:
Marino Brunori, Luciano Giuliodori, Massimo Catarini, Riccardo Centurioni, Claudia Polloni, Mario Ferranti, Monica Marconi, Maurizio Burattini, Marco Candela, Pietro Leoni, Massimo Offidani, Piero Galieni, Anna Mele, Laura Corvatta, Giuseppe Visani, Francesco Alesiani, Maria-Novella Piersantelli
Publikováno v:
Clinical Lymphoma and Myeloma. 8:294-299
Background Few studies have focused on factors affecting outcome in patients with multiple myeloma (MM) treated with thalidomide-based therapy. We investigated factors affecting response, progression-free survival (PFS), and overall survival (OS) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c22aab69025f23cca7b06267be751fae
https://doi.org/10.3816/clm.2008.n.041
https://doi.org/10.3816/clm.2008.n.041
Autor:
Luciano Giuliodori, Marino Brunori, Maria Novella Piersantelli, Piero Galieni, Massimo Offidani, Claudia Polloni, Anna Rita Scortechini, Attilio Olivieri, Serena Rupoli, Massimo Catarini, Antonella Poloni, Debora Capelli, Mario Ferranti, Maurizio Burattini, Pietro Leoni, Francesco Alesiani, Monica Marconi, Riccardo Centurioni, M Montanari, Laura Corvatta, Giuseppe Visani, Marco Candela
Publikováno v:
Blood. 108:2159-2164
We present the results of a phase 2 study using thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) in the treatment of 50 patients older than 65 years with newly diagnosed multiple myeloma. Thalidomide 100 mg was administered ora
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9f5a32ff026f49de631f9695d0a13b0
https://doi.org/10.1182/blood-2006-03-013086
https://doi.org/10.1182/blood-2006-03-013086
Autor:
Pietro Leoni, Lara Malerba, Esther Manso, Maria-Novella Piersantelli, Massimo Offidani, Laura Corvatta
Publikováno v:
Supportive Care in Cancer. 14:874-877
The objective of this study was to assess the utility of C-reactive protein (CRP) on differential diagnosis of pulmonary infiltrates occurring in 143 febrile patients with hematologic malignancies. Serum CRP level, measured on the first day of pneumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3d52a6e1b8bee5264ccdb67fd1430a2
https://doi.org/10.1007/s00520-006-0030-0
https://doi.org/10.1007/s00520-006-0030-0
Autor:
Pietro Leoni, Laura Corvatta, Antonio Palumbo, Massimo Offidani, Maria-Novella Piersantelli, Sara Bringhen, Patrizia Falco, Monica Marconi, Ilaria Avonto, Mario Boccadoro, Claudia Polloni
Publikováno v:
European journal of haematology. 78(4)
Objectives: Nearly all patients with multiple myeloma (MM) relapse or become refractory to front-line therapy. Several salvage therapies have been explored, but the optimal combination regimen has not been defined. We performed a case-matched study c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcd6e21d15a535ae383b13ed028d3bbe
https://pubmed.ncbi.nlm.nih.gov/17286608
https://pubmed.ncbi.nlm.nih.gov/17286608
Autor:
Massimo, Offidani, Laura, Corvatta, Monica, Marconi, Giuseppe, Visani, Francesco, Alesiani, Marino, Brunori, Piero, Galieni, Massimo, Catarini, Maurizio, Burattini, Riccardo, Centurioni, Serena, Rupoli, Anna Rita, Scortechini, Luciano, Giuliodori, Marco, Candela, Debora, Capelli, Mauro, Montanari, Attilio, Olivieri, Maria-Novella, Piersantelli, Pietro, Leoni
Publikováno v:
Haematologica. 91(1)
The aim of this prospective, multicenter, phase II study was to investigate the combination of pegylated liposomal doxorubicin (Caelyx) 40 mg/m2 on day 1 every 28 days, dexamethasone 40 mg p.o. on days 1-4 and 9-12 and thalidomide 100 mg daily in 50
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8e0c6cbbc2e0bc58e1569371d5a96440
https://pubmed.ncbi.nlm.nih.gov/16434383
https://pubmed.ncbi.nlm.nih.gov/16434383
Autor:
Monica Marconi, Maurizio Burattini, Pietro Leoni, Arduino Samori, Marino Brunori, Luisa Minnucci, Massimo Catarini, Anna Mele, Laura Corvatta, Maria-Novella Piersantelli, Silvia Gentili, Massimo Offidani, Lara Malerba, Claudia Polloni, Francesco Alesiani, Miriana Ruggieri
Publikováno v:
Blood. 112:5191-5191
New drugs such as thalidomide, bortezomib and lenalidomide have expanded the therapeutic options for MM while improving outcome in both young and elderly patients. However, the best novel agents sequence in the therapeutic strategy for MM is still no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12119d5376d14e3bf21957ef3047c7fc
https://doi.org/10.1182/blood.v112.11.5191.5191
https://doi.org/10.1182/blood.v112.11.5191.5191
Autor:
Attilio Olivieri, Marco Candela, Pietro Leoni, Maurizio Burattini, Luciano Giuliodori, Marino Brunori, Laura Corvatta, Massimo Catarini, Anna Mele, Riccardo Centurioni, Piero Galieni, Giuseppe Visani, Mario Ferranti, Silvia Gentili, Arduino Samori, Monica Marconi, Maria-Novella Piersantelli, Massimo Offidani, Claudia Polloni, Francesco Alesiani
Publikováno v:
Blood. 112:5186-5186
Previously we reported the outcome of 50 patients treated with an induction ThaDD regimen followed by a randomized maintenance therapy with a-Interferon or thalidomide and low-dose dexamethasone. At present, 88 patients with newly diagnosed MM have b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3adb436a8e0ada4cbf4132d5a10b1ae
https://doi.org/10.1182/blood.v112.11.5186.5186
https://doi.org/10.1182/blood.v112.11.5186.5186